Tuesday, 21 July 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 21 July 2026
News

Why Lilly turned down PBS listing

Posted 20 July 2026 PM

The ultimate roadblock in Eli Lilly accepting the PBAC's recommendation to list Mounjaro on the PBS has been revealed - with neither the PBAC nor the company wanting to be responsible for the off-label use of one of the world's biggest drugs.

When the PBAC recommended Mounjaro be subsidised on the PBS for type 2 diabetes mellitus in its March meeting Lilly immediately rejected the proposal. One of the reasons it gave was the price in the recommendation.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (19)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.